论文部分内容阅读
目的观察孟鲁司特咀嚼片联合治疗小儿喘息性支气管肺炎的临床疗效。方法将124例喘息性支气管肺炎患儿随机分为观察组和对照组各62例。其中对照组给予常规治疗,主要包括止咳化痰、解痉平喘、抗感染、雾化吸入等,观察组在对照组的基础上加服孟鲁司特钠咀嚼片。结果观察组总有效率为95.2%高于对照组的83.9%,差异有统计学意义(P<0.05);治疗后观察组的肺功能指标第1秒用力呼气容积占用力肺活量比(FEV1/FVC)及呼气峰值流速(PEF)实测值/预测值均优于对照组,差异均有统计学意义(P<0.05);2组不良反应发生率比较差异无统计学意义(P>0.05)。结论孟鲁司特咀嚼片联合治疗小儿喘息性支气管肺炎安全有效、服用方便,能够显著改善患儿的临床症状和肺功能。
Objective To observe the clinical efficacy of montelukast chewable tablet in children with asthmatic bronchopneumonia. Methods 124 cases of wheezy bronchopneumonia were randomly divided into observation group and control group, 62 cases each. The control group was given routine treatment, including cough and phlegm, antispasmodic and antiasthmatic, anti-infection and inhalation of atomization. The observation group was given montelukast sodium chewable tablets on the basis of the control group. Results The total effective rate in the observation group was 95.2%, which was significantly higher than that in the control group (83.9%, P <0.05). After treatment, the FEV1 / (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05), but there was no significant difference between the two groups (P> 0.05) . Conclusion Montelukast chewable tablets combined treatment of asthmatic bronchial pneumonia in children safe and effective, easy to take, can significantly improve the clinical symptoms and lung function in children.